Navigation Links
Warwick joins $3.4 million Anglo-Canadian quest for new weapons in war against antibiotic resistance
Date:1/9/2012

University of Warwick researchers have teamed up with Canadian scientists on a 2.2 million project to search for new antibiotics which will beat resistance in deadly "superbugs".

The University of Warwick is part of a transatlantic team funded by the Canada/UK Partnership on Antibiotic Resistance, a collaboration between the UK's Medical Research Council (MRC) and the Canadian Institutes of Health Research (CIHR).

The four-year project will support high-quality research into alternatives to existing antibiotics whose effectiveness is being challenged by increasing resistance in bacteria such as E. coli and MRSA.

Professor Chris Dowson, who is leading the project at the University of Warwick, said: "Growing antibiotic resistance to the current generation of antibiotics is of huge concern worldwide.

"Antibiotics underpin many aspects of healthcare - from cancer treatment through to surgery but the pace of antibiotic resistance in some bacteria is speeding up.

"Coupled with that, there is a worrying lack of new antibiotic drugs coming through the pipeline from private drug companies.

"That's why public funding for projects like this is so vital.

"Governments need to take responsibility for funding early-stage drug discovery as we face an increasing vacuum of antibiotic research within the pharmaceutical industry."

The Anglo-Canadian partnership takes advantage of the strong academic and clinical research strengths that exist in both Canada and the UK.

The University of Warwick is part of a team in the UK including the universities of Birmingham, Sheffield and Newcastle, working alongside the universities of Guelph, McMaster, Laval and British Columbia in Canada, which will focus on increasing understanding of bacterial cell wall growth in a bid to find new targets for new antibiotics.

Dr David Roper of the University of Warwick, School of Life Sciences and co-director of the project in the UK said: "Researchers on both sides of the Atlantic will be working in teams together exploring and exploiting aspects of the way in which bacteria synthesise their cell walls as they grow.

"Many current antibiotics, including penicillin, target this process and we think there are many new aspects to exploit, if we understood the process better.

"Our coordinated research efforts will be to further define the biological elements of how bacteria build their cell walls and discover new chemicals that interfere with that process.

"Research teams in Canada and the UK have unique facilities and expertise to do this and for the first time funding from MRC and CIHR is being used to combine those assets."

Research at the University of Warwick benefits from equipment provided through funding from Advantage West Midlands' Birmingham Science City, which will also contribute to this programme.


'/>"/>

Contact: Anna Blackaby
a.blackaby@warwick.ac.uk
44-247-657-5910
University of Warwick
Source:Eurekalert

Related medicine news :

1. Warwick scientists discover how daughter cells receive the same number of chromosomes
2. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
3. AMA Joins First Lady in Fight Against Childhood Obesity
4. The West Clinic Joins Cancer Clinics of Excellence (CCE)
5. Orthopaedic Physician Dr. Brett Smith Joins Baptist Health Care as Total Joint Specialist
6. Longtime Quality Assurance Executive Randy Johnson Joins White Pine Systems as Vice President of Product Services
7. Peter Harker Joins Prometheus Research as Vice President of Sales
8. Tom Brunelle Joins StatCom as Enterprise VP, Northeast Region
9. Christina Hurnyak, Veteran Personal Injury Attorney, Joins Rudberg Law Offices, LLC
10. Don Blumenthal Joins White Pine Systems as Chief Compliance Officer
11. CURE Magazine Joins US Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, ... University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) ... program, developed in association with efforts by the American College of Surgeons, U.S. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... laboratory instruments are critical to ensuring high-quality results and maintaining GMP and USP ... of Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... ... 28, 2017 , ... With less than 10,000 dermatologists in the United States ... be limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... customer online, today released its inaugural survey on the State of Acne in America. ...
(Date:3/28/2017)... ... , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio ... country to sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National ... helped propel the clinic from a small start-up to number 78 in the country ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to ... of business channels. , While many results are clear, much of PR is hard ... , When it comes to measurement, firms should always take an all-inclusive approach that ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... , March 28, 2017 ... research with Cambridge ... Consortium   The Milner Therapeutics Institute today announces ... Elysium Health has committed significant investment for collaborative projects with ... next four years. This is the first major research investment ...
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
Breaking Medicine Technology: